Aflibercept shows promising data for nonproliferative DR

aflibercept-shows-promising-data-for-nonproliferative-dr.jpg

MAR 20, 2018

By Keng Jin Lee

Regeneron Pharmaceuticals, Inc.

Retina/Vitreous

Topline results from a phase 3 trial show that aflibercept effectively reversed nonproliferative diabetic retinopathy (NPDR) progression, according to an announcement by Regeneron Pharmaceuticals.

The double-masked PANORAMA trial enrolled 402 patients who had moderately severe or severe NPDR without diabetic macular edema (DME). Patients were randomized to an observational sham injection group or 1 of 2 aflibercept treatment groups (i.e., 3 or 5 initial monthly doses, followed by an injection every 8 weeks).

At the primary endpoint of 24 weeks, 58% of patients in the aflibercept arms experienced a 2-step or greater improvement from baseline on the Diabetic Retinopathy Severity Scale, compared with 6% in the sham arm. Patients received an average of 4.4 aflibercept injections during that period.

There were no new safety signals in the trial. One case of mild intraocular inflammation occurred in the aflibercept group.

"This is the first time a therapy has demonstrated it can reverse disease progression in patients with moderately severe to severe non-proliferative diabetic retinopathy without diabetic macular edema, in a trial specifically designed to study this population," said George D. Yancopoulos, MD, PhD, president and chief scientific officer of Regeneron. "Patients in the trial continue to be evaluated to determine if Eyelea can prevent progression to neovascular vision-threatening complications or diabetic macular edema. We look forward to sharing one-year results later this year."

https://www.aao.org/headline/aflibercept-shows-promising-data-nonproliferative-

Comments

Post a Comment

Popular posts from this blog

Post-LASIK Refraction and Pregnancy – Much Ado About Nothing?

Image
Written by Dr. David Evans Last modified on August 23, 2018 During pregnancy, women experience a drastic shift in their hormonal balance that has a ripple effect throughout the body. The spike in hormones like progesterone, estrogen, prolactin, oxytocin and relaxin are all important for a healthy pregnancy, but these increased levels can also impact gastrointestinal processes, blood pressure, skin pigmentation and, you guessed it, ocular health. Due to refractive changes that often occur during pregnancy, most refractive surgeons advise against LASIK during pregnancy, instead suggesting women wait several months after giving birth before considering treatment. Women who have already undergone LASIK may then wonder if the changes in ocular health that can occur during and after pregnancy impact post-LASIK refraction. New research presented by John Kanellopoulos, MD, New York University Medical School, NY, and LaserVision.gr seems to throw cold water on any such concern. The Eyes an
Read more

I Spy a Stye in Your Eye

Image
Written by Dr. David Evans Last modified on August 6, 2018 What’s that small, red, pimple-like bump on your eyelid that’s causing so much discomfort? It’s probably a stye (sometimes referred to as a sty or hordeolum). Besides being difficult to say 5 times quickly, an eye stye is a type of localized infection that can occur along the base of your eyelashes or underneath your eyelid. Styes that form along the base of the eyelashes are called external styes. They typically occur as a result of an infected eyelash hair follicle and look like the type of pimple that occurs when your pores are clogged with dirt and oil. Styes that form inside the eyelid are called internal styes. Similar to external styes, they are caused by an infection of an oil-producing gland behind the eyelid rather than an eyelash hair follicle. Internal styes result in generalized swelling of the eyelid rather than forming a pimple-like bump. Stye Symptoms As a stye develops, you might begin to experience pain
Read more